Handelsbanken Fonder AB Has $33.18 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Handelsbanken Fonder AB decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 28.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 188,209 shares of the medical research company’s stock after selling 75,454 shares during the period. Handelsbanken Fonder AB’s holdings in IQVIA were worth $33,181,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of IQV. American National Bank & Trust acquired a new position in IQVIA in the first quarter valued at about $26,000. ST Germain D J Co. Inc. increased its holdings in IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock worth $34,000 after purchasing an additional 76 shares in the last quarter. GKV Capital Management Co. Inc. bought a new position in IQVIA in the 4th quarter valued at approximately $39,000. Lee Danner & Bass Inc. acquired a new position in shares of IQVIA during the fourth quarter worth $44,000. Finally, Zions Bancorporation N.A. grew its position in shares of IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after buying an additional 85 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of analyst reports. Redburn Partners set a $188.00 target price on shares of IQVIA in a research note on Friday, May 23rd. Barclays dropped their price objective on shares of IQVIA from $170.00 to $165.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 7th. Mizuho reduced their target price on shares of IQVIA from $210.00 to $190.00 and set an “outperform” rating for the company in a research note on Thursday, May 15th. JPMorgan Chase & Co. cut their price objective on IQVIA from $232.00 to $177.00 and set an “overweight” rating on the stock in a research report on Monday, May 19th. Finally, HSBC cut shares of IQVIA from a “buy” rating to a “hold” rating and lowered their price target for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Eight equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $226.32.

IQVIA Stock Performance

NYSE IQV opened at $159.70 on Wednesday. The firm has a market cap of $27.63 billion, a price-to-earnings ratio of 21.29, a PEG ratio of 1.99 and a beta of 1.28. The company has a 50-day simple moving average of $147.13 and a two-hundred day simple moving average of $178.43. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $252.88.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The company had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. During the same period in the previous year, the firm earned $2.54 earnings per share. The firm’s revenue for the quarter was up 2.5% on a year-over-year basis. On average, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.